These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 12535291

  • 1. Treating interdialytic hyperkalemia with fludrocortisone.
    Imbriano LJ, Durham JH, Maesaka JK.
    Semin Dial; 2003; 16(1):5-7. PubMed ID: 12535291
    [Abstract] [Full Text] [Related]

  • 2. Effect of fludrocortisone acetate on reducing serum potassium levels in patients with end-stage renal disease undergoing haemodialysis.
    Kim DM, Chung JH, Yoon SH, Kim HL.
    Nephrol Dial Transplant; 2007 Nov; 22(11):3273-6. PubMed ID: 17616536
    [Abstract] [Full Text] [Related]

  • 3. Fludrocortisone for the treatment of heparin-induced hyperkalemia.
    Sherman DS, Kass CL, Fish DN.
    Ann Pharmacother; 2000 May; 34(5):606-10. PubMed ID: 10852087
    [Abstract] [Full Text] [Related]

  • 4. Potassium-lowering effect of mineralocorticoid therapy in patients undergoing hemodialysis.
    Furuya R, Kumagai H, Sakao T, Maruyama Y, Hishida A.
    Nephron; 2002 May; 92(3):576-81. PubMed ID: 12372940
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Exogenous mineralocorticoid hormone improves predialysis hyperkalemia in anephric man.
    Whalen JE, Cohen LH.
    Proc Clin Dial Transplant Forum; 2002 May; 8():1-4. PubMed ID: 756027
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Hyporeninemic hypoaldosteronism, sodium wasting and mineralocorticoid-resistant hyperkalemia in two patients with obstructive uropathy.
    Pelleya R, Oster JR, Perez GO.
    Am J Nephrol; 1983 May; 3(4):223-7. PubMed ID: 6351617
    [Abstract] [Full Text] [Related]

  • 11. Control of hyperkalemia with fludrocortisone in a patient with systemic lupus erythematosus.
    Dreyling KW, Wanner C, Schollmeyer P.
    Clin Nephrol; 1990 Apr; 33(4):179-83. PubMed ID: 2350905
    [Abstract] [Full Text] [Related]

  • 12. Current and future potassium binders.
    Bakris GL.
    Nephrol News Issues; 2016 Apr; 30(4):suppl 27-31. PubMed ID: 27254903
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Aldosterone resistance in kidney transplantation is in part induced by a down-regulation of mineralocorticoid receptor expression.
    Heering PJ, Kurschat C, Vo DT, Klein-Vehne N, Fehsel K, Ivens K.
    Clin Transplant; 2004 Apr; 18(2):186-92. PubMed ID: 15016134
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Hyperkalemia across the Continuum of Kidney Function.
    Palmer BF, Clegg DJ.
    Clin J Am Soc Nephrol; 2018 Jan 06; 13(1):155-157. PubMed ID: 29114006
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.